Publications by authors named "Martin Stern"

Claim this Profile
P
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers.
Sébastien Benzekry, Mélanie Karlsen, Célestin Bigarré, Abdessamad El Kaoutari, Bruno Gomes, Martin Stern

Clin Pharmacol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic immune response to a CD40 agonist antibody in nonhuman primates.
David L Caudell, Gregory O Dugan, Galina Babitzki, Christine Schubert, Annamaria Braendli-Baiocco, Martin Stern

J Leukoc Biol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches.
Benjamin Ribba, Andreas Roller, Hans-Joachim Helms, Martin Stern, Conrad Bleul

Front Pharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Gabrielle Leclercq, Hélène Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Martin Stern

J Immunother Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Katelyn T Byrne, Courtney B Betts, Rosemarie Mick, Shamilene Sivagnanam, David L Bajor, Martin Stern

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma.
Astrid Tschan-Plessl, Christian P Kalberer, Ronja Wieboldt, Martin Stern, Uwe Siegler

Cytotherapy· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283 (Revision 1).

EFSA J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific and technical guidance for the preparation and presentation of a dossier for evaluation of an infant and/or follow-on formula manufactured from protein hydrolysates (Revision 1).

EFSA J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance on the preparation and submission of the notification and application for authorisation of traditional foods from third countries in the context of Regulation (EU) 2015/2283 (Revision 1).

EFSA J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance on the scientific requirements for health claims related to muscle function and physical performance: (Revision 1).

EFSA J· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of seed oil for extended uses in vegetable oils and milk and in yellow fat and cream-based spreads up to 30% (w/w).

EFSA J· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update of the tolerable upper intake level for vitamin D for infants.

EFSA J· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of xylo-oligosaccharides (XOS) as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of egg membrane hydrolysate as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symbiosal and lowering of blood pressure and reduced risk of hypertension: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006.

EFSA J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of shrimp peptide concentrate as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Black tea and improvement of attention: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of d-ribose as a novel food pursuant to Regulation (EU) 2015/2283.

EFSA J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbohydrate solutions and contribute to the improvement of physical performance during a high-intensity and long-lasting physical exercise: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xanthohumol in XERME, a xanthohumol-enriched roasted malt extract, and protection of DNA from oxidative damage: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Black tea and maintenance of normal endothelium-dependent vasodilation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.

EFSA J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health: (Revision 1).

EFSA J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis